The current biotech IPO market remains surprisingly strong and resilient. One of the characteristics of biotech IPO performance over the past eight years has been its dispersion, a feature that continues in the current environment. The author examines post-IPO value creation and destruction.
Value Creation And Destruction: Dispersion Of Performance In Biotech IPOs
